Хайлтын үр дүнгүүд - Kyle J. MacBeth

  • 17-н 1 - 17 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies -н Eric Laille, Tao Shi, Guillermo Garcia‐Manero, Christopher R. Cogle, Steven D. Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J. MacBeth

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism

    The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism -н Daniela Buglio, Vidya Mamidipudi, Noor M. Khaskhely, Helen Brady, Carla Heise, Jeffrey M. Besterman, Robert E. Martell, Kyle J. MacBeth, Anas Younes

    Хэвлэсэн 2010
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome

    Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome -н Kevin K. Leung, Aaron Nguyen, Tao Shi, Lin Tang, Xiaochun Ni, Laure Escoubet, Kyle J. MacBeth, Jorge DiMartino, James A. Wells

    Хэвлэсэн 2018
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

    A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines -н Paul W. Hollenbach, Aaron Nguyen, Helen Brady, Michelle M. Williams, Yuhong Ning, Normand Richard, Leslie A. Krushel, Sharon L. Aukerman, Carla Heise, Kyle J. MacBeth

    Хэвлэсэн 2010
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

    Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia -н Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle, Renee Ward, Tao Shi, Kyle J. MacBeth, Eric Laille, Heidi Giordano, Sarah Sakoian, Elias Jabbour, Hagop M. Kantarjian, Barry Skikne

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

    A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes -н Jing Fang, Xiaona Liu, Lyndsey Bolanos, Brenden Barker, Carmela Rigolino, Agostino Cortelezzi, Esther Natalie Olíva, Maria Cuzzola, H. Leighton Grimes, Celia Fontanillo, Kakajan Komurov, Kyle J. MacBeth, Daniel T. Starczynowski

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes -н Guillermo Garcia‐Manero, Steven D. Gore, Suman Kambhampati, Bart L. Scott, Ayalew Tefferi, Christopher R. Cogle, William J. Edenfield, Joel Hetzer, Kailash Kumar, Eric Laille, Tao Shi, Kyle J. MacBeth, B. Skikne

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care -н Hartmut Döhner, Anna Dolnik, Lin Tang, John F. Seymour, Mark D. Minden, Richard M. Stone, Teresa Bernal, Haifa Kathrin Al‐Ali, Valeria Santini, Paresh Vyas, C.L. Beach, Kyle J. MacBeth, Barry Skikne, S. Songer, Nora Tu, Lars Bullinger, Hervé Dombret

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) -н Leonie Saft, Masoud Karimi, Mehran Ghaderi, András Matolcsy, G J Mufti, Austin Kulasekararaj, Gudrun Göhring, Aristoteles Giagounidis, Dominik Selleslag, Petra Muus, Guillermo Sanz, Moshe Mittelman, David Bowen, Anna Porwit, Tommy Fu, Jay T. Backstrom, P. Fenaux, Kyle J. MacBeth, Eva Hellström‐Lindberg

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

    Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia -н Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton, Hagop M. Kantarjian, Robert H. Collins, Anthony S. Stein, Mark G. Frattini, Qiang Xu, Alessandra Tosolini, Wendy L. See, Kyle J. MacBeth, Samuel Agresta, Eyal C. Attar, Courtney D. DiNardo, Eytan M. Stein

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

    Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (... -н Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Pau Montesinos Fernández, Andrew H. Wei, Stéphane de Botton, Amer M. Zeidan, Amir T. Fathi, Lynn Quek, Hagop M. Kantarjian, Mark G. Frattini, Frederik Lersch, Jing Gong, Aleksandra Franovic, Kyle J. MacBeth, Paresh Vyas, Hartmut Döhner

    Хэвлэсэн 2019
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

    Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS -н Jan Krönke, Emma C. Fink, Paul W. Hollenbach, Kyle J. MacBeth, Slater N. Hurst, Namrata D. Udeshi, Philip P. Chamberlain, D.R. Mani, Hon Wah Man, Anita K. Gandhi, Tanya Svinkina, Rebekka K. Schneider, Marie McConkey, Marcus Järås, Elizabeth A. Griffiths, Meir Wetzler, Lars Bullinger, Brian E. Cathers, Steven A. Carr, Rajesh Chopra, Benjamin L. Ebert

    Хэвлэсэн 2015
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

    Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib -н Lynn Quek, Muriel D. David, Alison Kennedy, Marlen Metzner, Michael Amatangelo, Alan H. Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens, Véronique Saada, Samar Alsafadi, M. S. Vijayabaskar, Andy Peniket, Olivier Bernard, Sam Agresta, Katharine Yen, Kyle J. MacBeth, Eytan M. Stein, George S. Vassiliou, Ross L. Levine, Stéphane de Botton, Anjan Thakurta, Virginie Penard‐Lacronique, Paresh Vyas

    Хэвлэсэн 2018
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    <i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

    <i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype -н David A. Sallman, Amy F. McLemore, Amy L. Aldrich, Rami S. Komrokji, Kathy L. McGraw, Abhishek Dhawan, Susan Geyer, Hsin‐An Hou, Erika A. Eksioglu, Amy Sullivan, Sarah Warren, Kyle J. MacBeth, Manja Meggendorfer, Torsten Haferlach, Steffen Boettcher, Benjamin L. Ebert, Najla H. Al Ali, Jeffrey E. Lancet, John L. Cleveland, Eric Padron, Alan F. List

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

    Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia -н Feng Wang, Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan, Keyur P. Patel, Kyle J. MacBeth, Bin Wu, Guowen Liu, Mark G. Frattini, Jairo Matthews, Latasha Little, Curtis Gumbs, Xingzhi Song, Jianhua Zhang, Erika J. Thompson, Tapan M. Kadia, Guillermo Garcia‐Manero, Elias Jabbour, Farhad Ravandi, Kapil N. Bhalla, Marina Konopleva, Hagop M. Kantarjian, P. Andrew Futreal, Koichi Takahashi

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

    Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib -н Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Gail J. Roboz, Manish R. Patel, Robert H. Collins, Ian W. Flinn, Mikkael A. Sekeres, Anthony S. Stein, Hagop M. Kantarjian, Ross L. Levine, Paresh Vyas, Kyle J. MacBeth, Alessandra Tosolini, Jason VanOostendorp, Qiang Xu, Ira Gupta, Thomas Lila, Alberto Risueño, Katharine Yen, Bin Wu, Eyal C. Attar, Martin S. Tallman, Stéphane de Botton

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

    Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition -н James J. Harding, Maeve A. Lowery, Alan H. Shih, Juan M. Schvartzman, Shengqi Hou, Christopher Famulare, Minal Patel, Mikhail Roshal, Richard Kinh Gian, Ahmet Zehir, Daoqi You, S. Duygu Selçuklu, Agnès Viale, Martin S. Tallman, David M. Hyman, Ed Reznik, Lydia W.S. Finley, Elli Papaemmanuil, Alessandra Tosolini, Mark G. Frattini, Kyle J. MacBeth, Guowen Liu, Bin Fan, Sung Choe, Bin Wu, Yelena Y. Janjigian, Ingo K. Mellinghoff, Luis A. Díaz, Ross L. Levine, Ghassan K. Abou‐Alfa, Eytan M. Stein, Andrew M. Intlekofer

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: